Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

FDA Reports New Risks Posed by Anemia Drugs

Filed January 4th, 2008 amy

U.S. officials announced Thursday two new studies which offer further evidence of the health risks posed by the anemia drugs known as erythropoiesis-stimulating agents (ESAs). The studies showed that patients with breast or advanced cervical cancer who took the drugs as treatment for chemotherapy-induced anemia died sooner or had more rapid tumor growth than patients not on the drugs, U.S. Food and Drug Administration officials said in a prepared statement.

On Nov. 8, the FDA approved new “black box” warnings on labels of the three ESAs — Aranesp, Epogen and Procrit. The warnings detailed the dangers to patients with cancer and patients with chronic kidney Ass und 10 nach dem Teilen zweier Asse gewinnt 3:2: Einem unbestatigten Bericht zufolge gewinnt im „Meskaki Casino die-besten-online-casinos.info “ in Iowa Ass und Zehn nach dem Teilen zweier Asse 3:2. failure. Those dangers include heart attack, stroke, heart failure and cancer tumor growth and shortened survival, the FDA said. Results of the two studies released Thursday were not among the six studies that led to the Nov. 8 label revision.

Taken together, all eight studies show more rapid tumor growth or shortened survival when patients with breast, non-small cell lung, head and neck, lymphoid or cervical cancers received ESAs compared to patients who didn’t get this therapy, the FDA said.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!